601
Showing 1 - 1 of 1
Pathological Myopic Choroidal Neovascularization Trial in BeiJing (601, Ranibizumab)
Recruiting
- Pathological Myopic Choroidal Neovascularization
- 601
- Ranibizumab
-
BeiJing, ChinaPeking Union Medical College Hospital
Jun 4, 2021